Tim Felton

CF-Tracker extended data

S Weinberg, Alex Robert Horsley, Eva Caamaño‐Gutiérrez, Michael M. Tunney et autres

gb, bd, au (code pays fourni par la source)

CF-Tracker extended data

S Weinberg, Alex Robert Horsley, Eva Caamaño‐Gutiérrez, Michael M. Tunney et autres

gb, bd, au (code pays fourni par la source)

SHORTER trial: protocol for a pragmatic, multicentre, randomised controlled trial of short-duration antibiotic therapy for critically ill patients with sepsis

Phil Mawson, Miranda Morton, Zoë Walmsley, Rebecca Wafer et autres

INTRODUCTION: Sepsis is a life-threatening syndrome resulting from a dysregulated immune response to an infection. Patients with sepsis can become critically ill and require advanced organ support in a hospital critical care setting. Antibiotics are lifesaving in sepsis, but overuse is associated …

gb, pl, us (code pays fourni par la source)

Time of day of cardiac surgery and postoperative outcomes in the UK : a secondary analysis of linked national datasets

Gareth B. Kitchen, Karen E. Thomas, Tim Felton, Hannah Durrington et autres

INTRODUCTION: Uncertainty remains regarding whether the time of day that cardiac surgery is performed affects postoperative outcomes or if the observed variation can be explained by patient or surgical factors. METHODS: A secondary analysis of prospectively collected data was conducted to examine …

gb (code pays fourni par la source)

Clinical effectiveness of procalcitonin‐ or C‐reactive protein‐guided antibiotic discontinuation protocols for adult patients who are critically ill with sepsis: a rapid systematic review and meta‐analysis

Sonya Rafiq, Chunhu Shi, Shraboni Ghosal, Paul M. Dark et autres

INTRODUCTION: Antibiotics are a first-line treatment for sepsis, with guidelines recommending a 7- to 10-day course. Prolonged antibiotic use carries significant risks, prompting growing interest in using inflammatory biomarkers, such as procalcitonin or C-reactive protein, to guide clinical decision-making on the duration …

gb, ca (code pays fourni par la source)

P94 The microbiota of the hospital environment

Danielle E. Weaver, Alexandra Verhey, Oluwafunmilayo Adungba, Luke Ward et autres

Abstract Background Healthcare-associated infections (HAIs) are a significant public health issue. HAIs cause extended hospital stays, increased mortality, reduced quality of life and cost the NHS an estimated £2.7 Billion annually. In 2023, the most reported HAI bacterial pathogens in England were …

gb, ca, us (code pays fourni par la source)

Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study

Rebecca Symes, Heather Whitaker, Shazaad S. Y. Ahmad, David Arnold et autres

gb, us (code pays fourni par la source)

Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19

Peter Horby, Leon Peto, Mark Robin Campbell, Rachel L. Wade et autres

SUMMARY Background The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial evaluated the effects of sixteen potential treatments for patients hospitalised with COVID-19. Dexamethasone (at a dose of 6mg daily), tocilizumab, baricitinib, and the monoclonal antibodies casirivimab-imdevimab and sotrovimab were shown to reduce …

gb, in, vn (code pays fourni par la source)

LC-MS/MS metabolomics unravels the resistant phenotype of carbapenemase-producing Enterobacterales

Breanna Dixon, Waqar Ahmed, Stephen James Fowler, Tim Felton et autres

INTRODUCTION: The degree of antimicrobial resistance demonstrated by carbapenemase-producing Enterobacterales (CPE) represents a growing public health challenge. Conventional methods for detecting CPE involve culture-based techniques with lengthy incubation steps. There is a need to develop rapid and accurate methods for the detection …

gb (code pays fourni par la source)

Defining how antibiotics disrupt lung immune responses in asthma and health

Tim Felton

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial

Alexander G. Mathioudakis, Andrew J. Higham, Sebastian G. Bate, Victoria Chatzimavridou-Grigoriadou et autres

Inhaled corticosteroids (ICSs) benefit patients with chronic obstructive pulmonary disease at high risk of exacerbations with raised blood eosinophil count (BEC). Emerging evidence suggests current smokers show a reduced response to ICS. This post-hoc analysis of the FLAME trial explored the impact …

gb, dk (code pays fourni par la source)